Buyer further builds cardiovascular pipeline with purchase of PRX004
Novo Nordisk has agreed to acquire the ATTR candidate PRX004 from Prothena for up to $1.2 billion. Novo was among companies that expressed to Prothena their interest in developing the humanized monoclonal antibody. [Novo Nordisk]
The deal, announced last week, gives Prothena $60 million in upfront cash and potentially up to $1.17 billion tied to achieving development, commercialization and net sales-based milestones, starting with $40 million if the anti-amyloid immunotherapy advances to Phase II . . .
